𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐚𝐧𝐝 𝐏𝐨𝐢𝐬𝐨𝐧𝐬 𝐁𝐨𝐚𝐫𝐝 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐏𝐫𝐢𝐨𝐫𝐢𝐭𝐢𝐞𝐬 𝐚𝐭 𝟒𝟓𝐭𝐡 𝐏𝐒𝐊 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞
Mombasa | June 20, 2025 — The regulatory session at the 45th Annual Scientific Conference of the Pharmaceutical Society of Kenya (PSK) 2025 provided a robust platform for dialogue on strengthening pharmaceutical regulation in Kenya. The session was chaired by Dr. F.M. Siyoi, Chief Executive Officer of the Pharmacy and Poisons Board (PPB).
In his opening remarks, PPB Chairman Dr. Charles Githinji reaffirmed the Board’s firm commitment to supporting pharmacists across all areas of practice.
“We are focused. We are listening. And I assure you—your concerns will be addressed through strong, responsive, and technically grounded leadership to make pharmacy thrive,” he said.
Dr. Githinji highlighted key priorities currently driving the Board’s agenda: enforcement of Good Pharmacy Practices, proper scheduling and classification of medicines, and close engagement with the Health Products and Technologies (HPTs) Bill, which is presently before the Senate.
“We are monitoring its progress to ensure that the voice of the pharmacy profession is reflected. Regulation is a core mandate of government, and I am personally committed to ensuring full implementation of the commitments we make,” he added.
The session drew strong engagement from key PPB directorates—Health Products and Technologies, Corporate Services, and Pharmacy Practice—who outlined regulatory progress and ongoing reforms.
Dr. Siyoi reiterated the Board’s dedication to raising regulatory standards across the country, noting that PPB is at an advanced stage in the journey toward achieving World Health Organization (WHO) Maturity Level 3 status.
Panelists also spotlighted priority actions underway to strengthen service delivery and enhance patient safety. These include proactive post-marketing surveillance, capacity-building in pharmacovigilance, initiation of bioequivalence studies, and the development of regulatory frameworks to guide specialization in pharmacy practice.
The session reinforced the Board’s position as a technically competent, stakeholder-driven institution working to secure a safe, responsive, and accountable pharmaceutical sector.